Bibliography
- Pharmaprojects database. © Informa UK Ltd; 2009
- Schafer EA, Narasimhan J, Venkatachari NJ, Ayyavoo V. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antivir Res 2006;72:224-32
- Timm A, Enzinger C, Felder E, Genetic stability of recombinant MVA-BN. Vaccine 2006;24:4618-21
- Billich A. AIDSVAX VaxGen. Curr Opin Investig Drugs 2004;5:214-21
- De Bruijne J, Bergmann J, Weegink C, JTK-652 is a novel HCV entry inhibitor: results of a Phase I study evaluating safety, tolerability and antiviral activity in chronic hepatitis C patients. Abstracts of the 44th Annual Meeting of the EASL. Available from: http://www.kenes.com/easl2009/Posters/Abstract822.htm
- Toniutto P, Fabris C, Bitetto D, Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007;8:150-8
- Coelmont L, Paeshuyse J, Windisch MP, Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006;50:3444-6
- Miller RL, Meng T-C, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008;21:69-87
- Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90
- Koga T, Masuda N, Kakuta M, Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:2849-54
- Hoshino K, Inoue K, Murakami Y, In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008;52:65-76
- Yamamoto T, Dohmae S, Saito K, Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals. Antimicrob Agents Chemother 2006;50:4077-86
- Yanagihara K, Seki M, Izumikawa K, Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Int J Antimicrob Agents 2006;28:212-6
- Black MT, Stachyra T, Platel D, Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 2008;52:3339-49
- Schneider T, Gries K, Josten M, The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother 2009;53:1610-8
- Burnie JP, Matthews RC, Carter T, Identification of an immunodominant ABC transporter in methicillin resistant Staphylococcus aureus infections. Infect Immun 2000;68:1610-8
- Rigg GP, Matthews RC, Donohoe MS, Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus [abstract no. E-1645]. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif. 2002 Sep 27-30; American Society for Microbiology; 2002
- Kurtz CB, Cannon EP, Brezzani A, GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45:2340-7
- Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:2202-4
- Kamai Y, Harasaki T, Fukuoka T, In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob Agents Chemother 2002;46:367-70
- Cohen J. Surprising AIDS vaccine success praised and pondered. Science 2009;326:26-7